US 10,870,648 B2 · Inhibiting CREB binding protein (CBP)

Abstract

The present disclosure is directed to inhibitors of the CBP/p300 family of bromodomains. The compounds can be useful in the treatment of disease or disorders associated with the inhibition of the CBP/p300 family of bromodomains. For instance, the disclosure is concerned with compounds and compositions for inhibition of the CBP/p300 family of bromodomains, methods of treating, preventing, or ameliorating diseases or disorders associated with the inhibition of CBP/p300 family of bromodomains, and methods of synthesis of these compounds.

Claims24

Dependent claims

A compound of Formula (I):

or a pharmaceutically acceptable salt thereof, wherein:
R1 is —OR5;
R5 is —C1C6alkyl;
R6 is phenyl optionally substituted with one or more R10;
R10 is each independently, at each occurrence, —C1-C6alkyl, halogen, —OC1-C6alkyl, —OC3-C6cycloalkyl, wherein each alkyl or cycloalkyl is optionally substituted with one or more —R12;
or wherein any two R10 when on non-adjacent atoms, can combine to form a bridging cycloalkyl or heterocyclyl;
or wherein any two R10 when on adjacent atoms, can combine to form a cycloalkyl, heterocyclyl, aryl or heteroaryl;
R12 is independently, at each occurrence, —C1-C6alkyl, —OH, or halogen.

5 more elements

Dependencies are inferred from the claim text.

Facts

Application

16/457,596Filed 28 Jun 2019 · us provisional application

Priority

29 Jun 2018

Published

US 2020/0002332 A12 Jan 2020

Granted

22 Dec 2020

Term ends

Not estimatedThe source records don’t support an estimate.

Classification4 codes

C07D 471/04
In which the condensed system contains two hetero rings: ortho-condensed systems
A61P 35/00
Antineoplastic agents
C07D
Heterocyclic compounds
A61P
Therapeutic uses of medicines

Inhibiting CREB binding protein (CBP)

Life of this patent

Inhibiting CREB binding protein (CBP)

Life of this patent

Abstract

Claims24